Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections (Q35905025)

11 August 2017

1 reference

title

Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections (English)

1 reference

11 August 2017

anti-retroviral agent

0 references

opportunistic infection

1 reference

2

Shan-Chwen Chang

1 reference

11 August 2017

Chien-Ching Hung

1

1 reference

PubMed ID

15456733

11 August 2017

language of work or name

English

0 references

publication date

29 September 2004

1 reference

Journal of Antimicrobial Chemotherapy

11 August 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

11 August 2017

54

1 reference

11 August 2017

5

1 reference

11 August 2017

849-853

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

11 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Hepatitis C and progression of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH438

21 January 2018

Identifiers

DOI

10.1093/JAC/DKH438

1 reference

11 August 2017

1 reference

PubMed ID

15456733